HighBeam QuickSearch
Get direct access to articles and research when you
add HighBeam to your browser's search toolbar.
|
-
-
Nippon Shinyaku, Apogepha Terminate Development of NS-8, for the Treatment of Overactive Bladder
-
JCNN News Summaries - Japan Corporate News Network; Jan 25, 2007; ; 364 Words
...JCN) - Nippon Shinyaku and Apogepha Arzneimittel GmbH announced on January 16 their...Concept study undertaken by Apogepha in Europe. NS-8 is a novel...Shinyaku and was licensed out to Apogepha in October 2003. Apogepha has...
-
-
Amdipharm gains UK rights for Detrunorm.(Brief Article)
-
Pharma Marketletter; Jul 26, 2004; 513 Words
...Detrunorm (propiverine), from Germany-based Apogepha Arzneimittel GmbH. The agent was previously licensed to Schering...Under the terms of the accord, the UK firm will pay Apogepha an undisclosed single cash payment. Upon transfer...
-
-
Japan stock market week to Jan 22, 2007.(Statistical data)
-
Pharma Marketletter; Jan 29, 2007; 700+ Words
...lost 0.2% because it terminated an agreement with APOGEPHA Arzneimittel GmbH of Germany for the development and marketing of NS...results of the proof-of-concept study conducted by APOGEPHA in Europe. These did not show sufficient efficacy...
|
|